These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 19669678

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
    Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.
    Health Technol Assess; 2008 May; 12(16):iii-iv, ix-201. PubMed ID: 18462575
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
    Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM.
    Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis).
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Trans Am Ophthalmol Soc; 2013 Sep; 111():56-69. PubMed ID: 24167325
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
    Elshout M, van der Reis MI, Webers CA, Schouten JS.
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1911-20. PubMed ID: 24777708
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR, Moride Y, Rochon S.
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [Abstract] [Full Text] [Related]

  • 14. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Rapuano S, Boyer D.
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
    Li H, Li X, Xie F.
    Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):426-33. PubMed ID: 25241975
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.